Impact of anti-androgenic therapies on COVID-19: an observational study in male population from a COVID-19 regional centre of Lombardy (Italy)

Massimo Lazzeri¹, Elena Azzolini², Nicolò Maria Buffi¹, ³, Vittorio Fasulo¹, Francesco Persico¹, Alberto Saita¹, Rodolfo Hurle¹, Giovanni Lughezzani¹, ³, Rosanna Asselta³, ⁴, Stefano Duga³, ⁴, Giorgio Guazzoni¹, ³ and Paolo Casale¹

1. Department of Urology, Istituto Clinico Humanitas IRCCS, Rozzano – Milano (Italy)
2. Department of Health Management, Istituto Clinico Humanitas IRCCS, Rozzano – Milano (Italy)
3. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele – Milano (Italy)
4. Istituto Clinico Humanitas IRCCS, Rozzano, Milano, Italy

Corresponding Author:
Massimo Lazzeri, Department of Urology, Istituto Clinico Humanitas IRCCS, via Manzoni 56 (20089) Rozzano – Milano (Italy). Email: massimo.lazzeri@humanitas.it
Abstract
There are gender differences in susceptibility and vulnerability to the Coronavirus disease 2019 (COVID-19). The S protein of coronaviruses facilitates viral entry into target cells and employs the host cellular serine protease Tmprss2 for S protein priming. The Tmprss2 gene expression is responsive to androgen stimulation and it could partially explain gender differences. We tested the hypothesis that men who received 5-Alpha reductase inhibitors (5ARIs) or androgen deprivation therapy (ADT) for prostate cancer could have a different susceptibility to COVID-19.

We carried out an observational study on patients who were referred to our COVID-19 regional centre in Lombardy from 1\textsuperscript{st} to 31\textsuperscript{st} March 2020. Data from 421 patients, 137 women (32.54\%) and 284 men (67.44\%) with laboratory-confirmed COVID-19, were included in this report. Overall 84 patients died: 28 women (33.33\%) and 56 men (66.67\%). Among men, 12 patients (4.22\%) reported assuming 5ARI treatment, and 6 were under ADT. Over 12 patients under 5ARIs, 3 (25\%) died; 2 deaths (33\%) were reported in patients under ADT. Our findings showed that only 4.22\% of the overall population received 5ARI anti-androgen therapy, a percentage, which revealed to be significantly lower (P<0.0001) than what observed in Italian men aged more than 40 years (14.97\%).
Main Text

Over the past 2 months, the Coronavirus disease 2019 (COVID-19) pandemic has marched relentlessly westward. Presently, Italy has one of the highest rates of SARS-CoV-2 infection in the world among large countries, with 258 cases per 100,000 people, and the highest mortality rate, 12.7% vs. an average value of 6.2% (as of April 13th 2020 [1]). Although sex-disaggregated data for COVID-19 in Italy show equal numbers of cases between men and women (men are 52.06%, data from the Italian National Institute of Health) [https://www.epicentro.iss.it/coronavirus/], there seem to be gender differences in vulnerability to the disease, with men more prone to have higher severity and lethality, independently of age; similar data were found also in the Chinese population [2]. Experience from past outbreaks shows the importance of incorporating a gender analysis into preparedness and response efforts to improve the effectiveness of health interventions and treatments [3]. There is the clinical need to consider the gender effects of the COVID-19 outbreak, both direct and indirect, and conduct an analysis of the gendered impacts of the multiple outbreaks, incorporating different variables.

The spike (S) protein of coronaviruses facilitates viral entry into target cells [4]. Entry depends on binding of the surface unit, S1, of the S protein to a cellular receptor, which facilitates viral attachment to the surface of target cells. In addition, entry requires S protein priming by cellular proteases, which entails S protein cleavage at the S1/S2 and the S2 sites and allows fusion of viral and cellular membranes, a process driven by the S2 subunit. SARS-S engages angiotensin converting enzyme 2 (ACE2) as the entry receptor and employs the cellular serine protease TMPRSS2 for S protein priming [5]. TMPRSS2 gene expression is responsive to androgen stimulation [6] and it was hypothesized that differences in TMPRSS2 expression levels might be implicated in the observed gender differences. [7]. Moreover, other genes modulated by sex hormones have been reported to impact on the immune system [8]. We hence tested the hypothesis that patients who received 5-Alpha reductase inhibitors (5ARIs) or androgen deprivation therapy (ADT) for prostate cancer (PCa) could have a different susceptibility and/or be more protected than men who don’t or women.

We carried out an observational longitudinal study on patients who were referred to our COVID-19 regional centre of Lombardy (Italy) from 1st to 31st March 2020, and were positive for SARS-CoV-2 virus according to the WHO guidance. The study was approved by the local Ethics
Committee of the Istituto Clinico Humanitas and conducted according to the Declaration of Helsinki. Patients with uncompleted chart data or who were unable to release, personally or by relatives, a complete medical and pharmacological history, were ruled out. Variables of interest were: i) patients who received 5ARIs (finasteride or dutasteride) in the last six months (chronic exposure) for the treatment of benign prostate hyper trophy (BPH); ii) patients who are under current ADT for PCa; iii) patients who failed ADT for PCa and presented with castration resistant prostate cancer (CRPC) or metastatic CRPC (mCRPC). The primary outcome of interest was prevalence and disease severity (alive vs. death) between patients who received hormonal therapy (finasteride/dutasteride/ADT) and those who do not. Descriptive statistical analysis was performed. Data from 421 patients, 137 women (32.54%) and 284 men (67.46%) with laboratory-confirmed COVID-19, were included in this report. The mean age was 64.14 ± 14.1 years; no statistically significant difference was found between women and men: 64.94 ±12.8 and 63.75 ± 14.6 (p=0.42), respectively. Overall, 84 patients died: 28 women (33.33%) and 56 men (66.67%). The mean age for alive vs. death was statistically significant: 61.41 yrs ± 13.5 vs. 75.08 ± 10.4 (p<0.001) respectively, with no differences between men and women. Among men, 12 patients (4.22%) reported assuming 5ARI treatment, 6 of them with a contemporary alpha-blocker (AB) drug, 14 (4.9%) patients have been taking AB, and 6 (2.1%) were under ADT; two of them suffered from mCRPC. Over 12 patients under 5ARIs, 3 (25%) died, among patients taking ADT 2 died. The mean age of men who died was higher than those who did not: 77.10 yrs ± 10.4 vs. 61.41 ± 9.5 (p<0.001). The overall lethality rate for male patients taking anti androgen therapies was 27.78%, higher than the one calculated for all male patients included in the study (19.17%). This can be explained by the higher age of males taking anti androgenic therapies (mean age 5ARI = 75.66 SD ±11.46).

COVID-19, has resulted in high rates of hospitalization, intensive care unit (ICU) admission and death in Italy [2]. As the availability of hospitals and beds are limited, knowledge of baseline characteristics and outcome is crucial for health and government officials involved in prevention and management of the outbreak. The description of cases, their medical history and drugs might help in identifying risk and protective factors. In this preliminary report we found that only 4.22% of the male patients received 5ARIs and 2.11% were on ADT. Cindolo et al. investigated the medical management of lower urinary tract symptoms (LUTS) related to BPH in the Italian population [9]. They found that the use of drugs prescribed for LUTS/BPH related symptoms has steadily increased over 5 years for 5ARIs (+49%). In Italian men, aged > 40 yrs., the overall
Exposure was of 14.97%, which increased to 23.4% in the range between 75-84 years old. This rate of exposure appeared significantly higher regard to what we observed (10.75% difference, 95% CI = 7.74-12.54%, p<0.0001; calculations based on data from the Italian National Institute of Statistics, reporting a male population over 40 years of 17.40 million people) [10]. As our study is a descriptive observational study in a highly selected population within a short time window, we cannot infer specific conclusions supporting, a protective effect for 5ARIs. However, our report suggests that reduced androgen stimulation might indeed represent a protective factor for the male sex. Beside the possible effect on TMPRSS2 expression, modulation of androgen stimulation can act on a number of other genes related to the immune response, reducing the differences between men and women.

Our study has several limitations. The sample size is small for an epidemiological survey, no correction for co-morbidities was done and no correlation between 5ARI/ADT and TMPRSS2 expression was investigated. Finally, no correlation with severity of disease, considering variables such as level of positive end-expiratory pressure (PEEP), fraction of inspired oxygen (FIo2), arterial partial pressure of oxygen (PaO2), or PaO2/FIO2 ratio was done.
References:

1. https://coronavirus.jhu.edu/map.html


7. Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. https://www.medrxiv.org/content/10.1101/2020.03.30.20047878v1

